Physician profile
Sam F Stea
NPI 1053396994
$1,013.08
in general payments reported to CMS, 2019-2025
15 companies · $78.65 in 2025
The $78.65 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2021: $209 · 2022: $106 · 2023: $18.12 · 2024: $343 · 2025: $78.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $439.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $283.32 | 2019-2025 | Veltassa, Korsuva |
| Sanofi-Aventis U.S. LLC | $125.00 | 2024 | |
| Veloxis Pharmaceuticals, INC. | $120.14 | 2021 | |
| Genzyme Corporation | $96.55 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $75.15 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $65.57 | 2019-2022 | |
| Amgen INC. | $57.67 | 2019-2024 | Tavneos |
| Travere Therapeutics, INC. | $50.49 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $37.71 | 2021 | |
| Covidien Lp | $21.22 | 2019 | |
| Ardelyx, INC. | $19.90 | 2024 | Ibsrela |
| Nxstage Medical, INC. | $19.29 | 2022 | |
| Shire North American Group INC | $16.14 | 2019 | |
| Akebia Therapeutics INC | $14.06 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Stea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.